In human medicine there have been many studies reporting the importance of evaluating serum ET-1 or big ET-1 in various diseases as a clinical marker, especially related to pulmonary hypertension and several tumors. In veterinary medicine, however, few studies have been performed on the clinical importance of serum ET-1 or big ET-1. In this study we explored the feasibility of using the serum big ET-1 as a clinical marker in dogs with various cardiopulmonary and neoplastic diseases. Pulmonary hypertension was diagnosed in dogs by echocardiography based on the velocity of tricuspid valve regurgitation. Serum big ET-1 and NT-pro BNP concentrations in these dogs were measured by ELISA and compared with those of healthy dogs. Serum big ET-1 concentration in dogs with various neoplastic diseases was also assessed and compared. Our results showed a significant increase of serum big ET-1 in dogs with pulmonary hypertension, lung tumor and hemangiosarcoma when compared to normal dogs. No significant difference was observed in NT-pro BNP concentration between healthy and pulmonary hypertension dogs. Although further studies are necessary, these findings point to the potential of serum big ET-1 as a clinical marker in canine pulmonary hypertension and for some tumor types. A 56-year-old man developed sudden dyspnoea after resection of choroidal melanoma in his left eyeball. Worsening hypoxia required intensive treatment, including percutaneous cardiopulmonary support. On contrast-enhanced computed tomography there was no evidence of either thrombi in the pulmonary arteries or obvious lung diseases. A Swan-Ganz catheter showed increased mean pulmonary arterial pressure and no elevation of pulmonary capillary wedge pressure. These findings were consistent with a diagnosis of pulmonary arterial hypertension. Because reports have described a significant relationship between melanoma and endothelin (ET)-1, we hypothesized that a substantial amount of ET-1 had been released from malignant melanoma cells during resection, thus triggering the pulmonary hypertensive crisis in our patient. The patient fully recovered after intensive treatment and administration of the endothelin receptor antagonist bosentan. The success of bosentan treatment, along with an extremely high level of ET-1 on pathologic analysis, confirmed our hypothesis regarding an increase in plasma ET-1 level -9.60 pg/mL (normal range b 2.3 pg/mL). Objective: The primary objective of the Phase I study was to assess the safety and tolerability of SPI-1620 administered to patients with recurrent or progressive carcinoma who had failed all standard therapy. Secondary objectives were to assess PK and PD profiles of SPI-1620, and to identify the optimum dose of SPI-1620 to be used in future Phase II studies. The pharmacokinetic properties of SPI-1620 will be presented. Methods: Eligible patients received SPI-1620 by intravenous infusion over 1 min in an accelerated dose escalation scheme. SPI-1620 doses ranged from 0.5 μg/m 2 to 15.1 μg/m 2 . Serial blood samples were collected from each patient prior to infusion (0 min) and at prespecified intervals from the start of the infusion. Human plasma samples were analyzed by a validated HPLC-MS/MS method. Descriptive PK parameters were determined by standard model independent methods based on the concentration-time data of each subject. Results & conclusion: The highest concentration of SPI-1620 was achieved by the end of infusion. SPI-1620 C max increased proportionally as a function of SPI-1620 dose while the AUC (0-T) increased in a more than dose proportional manner. The SPI-1620 T 1/2 was short and ranged from 4.38 min to 8.29 min. SPI-1620 had a low systemic clearance and small VD (approximately equal to the intravascular volume). The epithelial-mesenchymal transition (EMT) is known to play a crucial role in the aggressiveness of epithelial ovarian cancer (EOC), contributing to chemoresistance and cancer stem cell populations. In this tumor, the endothelin (ET)-1/endothelin A receptor (ETAR) axis, by regulating EMT and invasion, endows EOC cells with an increased chemoresistance. Here we examined whether β-arrestin-1 (β-arr1) can act as a nuclear hub orchestrating nuclear signaling in ETARdriven EMT and chemoresistance. A significant higher expression of β-arr1 and ET-1/ETAR and the stronger presence of β-arr1 in the nuclear compartment upon ETAR activation are present in chemoresistant cells, compared to sensitive cells. In the nuclei, β-arr1 robustly interacts with β-catenin to form a nuclear complex localized on the ET-1 promoter region, leading to transcription of ET-1, demonstrating that β-arr1 drives the positive inter-regulation of ET-1 itself. This autocrine circuit is involved in β-arr1-driven appearance of EMT features and acquisition of stem-cell like properties. Moreover, at functional level, chemoresistant cells, with high nuclear β-arr1, display higher invasive potential and increased resistance to chemotherapeutic drugs. These effects were inhibited by ET-1 receptor blockade with macitentan, or by β-arr1 nuclear mutant. 
